Oncogenic drivers in daily practice improve overall survival in patients ă with lung adenocarcinoma

Clarisse Fournier, L. Greillier (), F. Fina, V. Secq, I. Nanni-Metellus, A. Loundou, S. Garcia, L. Ouafik (), P. Tomasini and F. Barlesi ()
Additional contact information
A. Loundou: SPMC - Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants - AMU - Aix Marseille Université - APHM - Assistance Publique - Hôpitaux de Marseille
P. Tomasini: Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM] - APHM - Assistance Publique - Hôpitaux de Marseille - Hôpital Nord [CHU - APHM]
F. Barlesi: APHM - Assistance Publique - Hôpitaux de Marseille, OMIT - Multidisciplinary Oncology and Therapeutic Innovations Unit / Service d’Oncologie Multidisciplinaire et d’Innovations Thérapeutiques - Hôpital Nord [CHU - APHM]

Post-Print from HAL

Abstract: Background. - EGFR tyrosine kinase inhibitors and crizotinib are ă nowadays the optimal treatment for metastatic lung cancer with ă activation of EGFR mutations and ALK rearrangement. In addition, several ă targeted agents are in development for lung cancer with other ă oncodrivers. In France, since 2011, six oncodrivers are routinely tested ă in patients with stage IV. The aim of this study was to assess whether ă systematic detection of oncodrivers and matched targeted therapy improve ă overall survival in patients with advanced lung adenocarcinoma. ă Methods. - This study included all consecutive patients treated in our ă department for advanced lung adenocarcinoma from January 2012 to ă December 2013. We studied the impact in survival according to the ă presence of the driver and the targeted therapy. ă Results. - Among the 261 patients included, oncodrivers alterations were ă found in 43.5% of patients: EML4-ALK fusion genes (2.1%), EGFR ă (10.3%), KRAS (27.7%), BRAF (2.5%), HER2 (0.8%), and PI3KCA (0.8%) ă mutations. Twenty-nine percent of patients (n = 32) with oncodrivers ă received matched targeted therapy. Patient treated by targeted agent ă appropriate to an oncogenic driver had a median survival of 21.1 months ă (95% CI: 14.7-27.5). The patients (n=79) who did not receive targeted ă therapy had a median survival of 6.6 months (95% CI: 4.3-8.9). The ă patients (n = 150) without identified driver had a median survival of ă 9.7 months (95% CI: 6.7-11.7); P

Keywords: quality (search for similar items in EconPapers)
Date: 2016-11
References: Add references at CitEc
Citations:

Published in Revue des Maladies Respiratoires, 2016, 33 (9), pp.751-756. ⟨10.1016/j.rmr.2015.12.009⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-01482384

DOI: 10.1016/j.rmr.2015.12.009

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().